Mitiglinide Calcium

Mitiglinide calcium is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K channels in pancreatic beta-cells.

Product information

CAS Number: 145525-41-3

Molecular Weight: 668.88

Formula: C38H48CaN2O6

Synonym:

KAD-1229

S21403

Glufast

Chemical Name: calcium 2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoate

Smiles: [Ca+2].[O-]C(=O)C(CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)CC1C=CC=CC=1.[O-]C(=O)C(CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)CC1C=CC=CC=1

InChiKey: PMRVFZXOCRHXFE-RJAPBONKSA-L

InChi: InChI=1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17?;

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 5 mg/mL (14.95 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Mitiglinide Calcium inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells[1].

In Vivo:

Mitiglinide Calcium (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2].

References:

1. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25.
2. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7.

Products are for research use only. Not for human use.